Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,208,655
  • Shares Outstanding, K 60,455
  • Annual Sales, $ 3,834 M
  • Annual Income, $ 414,830 K
  • EBIT $ 1,268 M
  • EBITDA $ 1,907 M
  • 60-Month Beta 0.57
  • Price/Sales 1.84
  • Price/Cash Flow 4.20
  • Price/Book 1.73

Options Overview Details

View History
  • Implied Volatility 26.35% ( +1.80%)
  • Historical Volatility 38.65%
  • IV Percentile 5%
  • IV Rank 9.67%
  • IV High 48.24% on 07/18/24
  • IV Low 24.00% on 12/05/23
  • Put/Call Vol Ratio 0.09
  • Today's Volume 177
  • Volume Avg (30-Day) 151
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 4,055
  • Open Int (30-Day) 4,787

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 5.01
  • Number of Estimates 8
  • High Estimate 5.38
  • Low Estimate 4.57
  • Prior Year 4.40
  • Growth Rate Est. (year over year) +13.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.44 +16.44%
on 10/24/24
128.99 -3.02%
on 11/13/24
+11.98 (+10.59%)
since 10/21/24
3-Month
104.42 +19.80%
on 09/11/24
128.99 -3.02%
on 11/13/24
+10.74 (+9.39%)
since 08/21/24
52-Week
99.06 +26.29%
on 07/10/24
134.17 -6.76%
on 02/26/24
+6.83 (+5.77%)
since 11/21/23

Most Recent Stories

More News
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will...

CTMX : 0.8665 (-0.41%)
JAZZ : 125.10 (+4.91%)
CSTL : 28.88 (+1.51%)
SPRO : 1.1900 (-0.83%)
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?

Investors in Jazz Pharmaceuticals PLC JAZZ need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $65.00 Call had some of the highest implied...

JAZZ : 125.10 (+4.91%)
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

Axsome Therapeutics, Inc. AXSM incurred an adjusted loss of $1.34 per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.38. The company had incurred a loss...

JAZZ : 125.10 (+4.91%)
CSTL : 28.88 (+1.51%)
ANIP : 55.86 (+1.38%)
AXSM : 98.19 (+3.79%)
Jazz: Q3 Earnings Snapshot

Jazz: Q3 Earnings Snapshot

JAZZ : 125.10 (+4.91%)
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker

Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!

GOOG : 169.24 (-4.56%)
GOOGL : 167.63 (-4.74%)
JAZZ : 125.10 (+4.91%)
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.Here's...

JAZZ : 125.10 (+4.91%)
EXEL : 34.83 (+0.52%)
NVAX : 8.04 (-0.25%)
VNDA : 4.94 (+0.82%)
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?

Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.Auvelity...

JAZZ : 125.10 (+4.91%)
ACAD : 16.18 (-0.55%)
AXSM : 98.19 (+3.79%)
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

Axsome Therapeutics, Inc. AXSM announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.A final decision from the regulatory...

JAZZ : 125.10 (+4.91%)
AXSM : 98.19 (+3.79%)
KRYS : 182.29 (+2.35%)
FULC : 2.97 (-0.67%)
Jazz: Q2 Earnings Snapshot

Jazz: Q2 Earnings Snapshot

JAZZ : 125.10 (+4.91%)
S&P 500 and Nasdaq 100 Fall from Record Highs as Chip Stocks Retreat

The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.77%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.79%. Stock indexes...

$SPX : 5,948.71 (+0.53%)
SPY : 593.67 (+0.54%)
$DOWI : 43,870.35 (+1.06%)
DIA : 438.97 (+1.08%)
$IUXX : 20,740.78 (+0.36%)
QQQ : 504.98 (+0.36%)
ZNZ24 : 109-180 (+0.06%)
JBL : 130.64 (+1.92%)
QCOM : 155.46 (+0.77%)
MU : 102.76 (+4.46%)
MCHP : 66.51 (+2.13%)
WDC : 65.88 (+3.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 132.71
2nd Resistance Point 129.17
1st Resistance Point 127.14
Last Price 125.10
1st Support Level 121.57
2nd Support Level 118.03
3rd Support Level 116.00

See More

52-Week High 134.17
Last Price 125.10
Fibonacci 61.8% 120.76
Fibonacci 50% 116.61
Fibonacci 38.2% 112.47
52-Week Low 99.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar